Sana Biotechnology has a new $50 million tool in its toolbox. Sana signed an agreement with Beam Therapeutics for non-exclusive commercial rights to the Cambridge, Mass.-based biotech’s gene editing system,… Read More
Sana Biotechnology raised $587.5 million in an initial public offering, a significant cash haul that the 3-year-old Seattle company will use to continue a quest to treat disease using cutting-edge… Read More
Editor’s note: Sana Biotechnology priced shares on Wednesday evening, raising $587.5 million. See full story here. Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of… Read More
Sana Biotechnology CEO Steve Harr shed more light on one of most secretive, heavily funded startups in Seattle and the global biotech industry — detailing its plans to create tools… Read More
Sana Biotechnology today formally announced that it has raised more than $700 million in venture funding — one of the largest venture financing deals in the life sciences industry and… Read More
A quick gander at the GeekWire 200, our index of Pacific Northwest startups, shows the density of up-and-coming tech companies based in this region. That’s what makes the five nominees… Read More